JP5791064B2 - 医薬用組成物 - Google Patents

医薬用組成物 Download PDF

Info

Publication number
JP5791064B2
JP5791064B2 JP2010128057A JP2010128057A JP5791064B2 JP 5791064 B2 JP5791064 B2 JP 5791064B2 JP 2010128057 A JP2010128057 A JP 2010128057A JP 2010128057 A JP2010128057 A JP 2010128057A JP 5791064 B2 JP5791064 B2 JP 5791064B2
Authority
JP
Japan
Prior art keywords
angiogenesis
μmol
nitrite
nitrate
retinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010128057A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011037830A (ja
Inventor
順也 藤森
順也 藤森
秀運 馬場
秀運 馬場
敏規 村田
敏規 村田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Air Water Inc
Original Assignee
Air Water Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2010128057A priority Critical patent/JP5791064B2/ja
Application filed by Air Water Inc filed Critical Air Water Inc
Priority to PCT/JP2010/061768 priority patent/WO2011007755A1/ja
Priority to CN201080032449.6A priority patent/CN102470146B/zh
Priority to EP20100799813 priority patent/EP2455091A4/en
Priority to IN1285DEN2012 priority patent/IN2012DN01285A/en
Priority to US13/383,805 priority patent/US20120114768A1/en
Publication of JP2011037830A publication Critical patent/JP2011037830A/ja
Priority to US13/897,603 priority patent/US8974836B2/en
Application granted granted Critical
Publication of JP5791064B2 publication Critical patent/JP5791064B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2010128057A 2009-07-17 2010-06-03 医薬用組成物 Expired - Fee Related JP5791064B2 (ja)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2010128057A JP5791064B2 (ja) 2009-07-17 2010-06-03 医薬用組成物
CN201080032449.6A CN102470146B (zh) 2009-07-17 2010-07-12 血管新生控制组合物以及控制血管新生的方法
EP20100799813 EP2455091A4 (en) 2009-07-17 2010-07-12 ANGIOGENESIS REGULATION COMPOSITION AND ANGIOGENESIS REGULATION METHOD
IN1285DEN2012 IN2012DN01285A (https=) 2009-07-17 2010-07-12
PCT/JP2010/061768 WO2011007755A1 (ja) 2009-07-17 2010-07-12 血管新生制御組成物および血管新生制御方法
US13/383,805 US20120114768A1 (en) 2009-07-17 2010-07-12 Angiogenesis regulating composition and method for regulating angiogenesis
US13/897,603 US8974836B2 (en) 2009-07-17 2013-05-20 Angiogenesis regulating composition and method for regulating angiogenesis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009168928 2009-07-17
JP2009168928 2009-07-17
JP2010128057A JP5791064B2 (ja) 2009-07-17 2010-06-03 医薬用組成物

Publications (2)

Publication Number Publication Date
JP2011037830A JP2011037830A (ja) 2011-02-24
JP5791064B2 true JP5791064B2 (ja) 2015-10-07

Family

ID=43449363

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010128057A Expired - Fee Related JP5791064B2 (ja) 2009-07-17 2010-06-03 医薬用組成物

Country Status (6)

Country Link
US (2) US20120114768A1 (https=)
EP (1) EP2455091A4 (https=)
JP (1) JP5791064B2 (https=)
CN (1) CN102470146B (https=)
IN (1) IN2012DN01285A (https=)
WO (1) WO2011007755A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6284341B2 (ja) 2012-10-24 2018-02-28 国立大学法人東京農工大学 未熟児網膜症の治療又は予防剤、未熟児網膜症の検査方法及び未熟児網膜症の治療又は予防物質のスクリーニング方法
JP6042197B2 (ja) * 2012-12-11 2016-12-14 エア・ウォーター株式会社 肺障害治療剤
JP6153838B2 (ja) * 2013-10-04 2017-06-28 エア・ウォーター株式会社 血管透過性抑制剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731294A (en) 1993-07-27 1998-03-24 Hybridon, Inc. Inhibition of neovasularization using VEGF-specific oligonucleotides
CA2176934A1 (en) * 1993-11-17 1995-05-26 Ramnath Sasisekharan Method for inhibiting angiogenesis using heparinase
JPH10273450A (ja) * 1997-03-27 1998-10-13 Toagosei Co Ltd 眼内血管新生性疾患治療薬
WO1998043621A1 (en) * 1997-03-31 1998-10-08 The Children's Medical Center Corporation Nitrosylation to inactivate apoptotic enzymes
AU3109199A (en) * 1998-03-25 1999-10-18 Large Scale Biology Corporation Benzoates derivatives for inhibiting angiogenesis
AU3609300A (en) * 1999-03-01 2000-09-21 Human Genome Sciences, Inc. Human serpin proteins
AU779991B2 (en) * 1999-08-10 2005-02-24 Board Of Regents, The University Of Texas System Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight
JP4210826B2 (ja) 2001-01-19 2009-01-21 参天製薬株式会社 ウレア誘導体を有効成分とする血管新生阻害剤
US20070135380A1 (en) * 2005-08-12 2007-06-14 Radiorx, Inc. O-nitro compounds, pharmaceutical compositions thereof and uses thereof
US20080069904A1 (en) * 2006-07-18 2008-03-20 Oronsky Bryan T Inhibition of angiogenesis through nitric oxide tachyphylaxis
JP2008110950A (ja) 2006-10-31 2008-05-15 Japan Health Science Foundation 糖尿病網膜症の治療方法
CA2678097C (en) * 2007-02-26 2023-03-14 Jon Lundberg New use of nitrites and nitrates and compositions containing these
ES2442720T3 (es) * 2008-07-31 2014-02-13 Nicox S.A. Glucocorticoides unidos a ésteres de nitrato por medio de un enlazador aromático en posición 21 y su uso en oftalmología
US20100197702A1 (en) * 2009-02-04 2010-08-05 Hellberg Mark R Ophthalmic composition with nitric oxide donor compound and method of forming and using same

Also Published As

Publication number Publication date
US20120114768A1 (en) 2012-05-10
WO2011007755A1 (ja) 2011-01-20
CN102470146B (zh) 2014-09-10
CN102470146A (zh) 2012-05-23
US20130251823A1 (en) 2013-09-26
EP2455091A4 (en) 2012-12-19
IN2012DN01285A (https=) 2015-05-15
JP2011037830A (ja) 2011-02-24
EP2455091A1 (en) 2012-05-23
US8974836B2 (en) 2015-03-10

Similar Documents

Publication Publication Date Title
JP2022116191A (ja) 異常な新生血管形成を伴う眼疾患を処置するためにニンテダニブを使用する組成物および方法
JP6931004B2 (ja) ２−ブロモ−１−（３，３−ジニトロアゼチジン−１−イル）エタノンの静脈内投与のための組成物および方法
JP5212849B2 (ja) 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
HRP20040406A2 (en) Methods for treating ocular neovascular diseases
Xia et al. Intravitreal conbercept improves outcome of proliferative diabetic retinopathy through inhibiting inflammation and oxidative stress
RU2519739C2 (ru) Офтальмологическое фармацевтические композиции для неоангиогенных патологий глаза
EA022873B1 (ru) Применение ингибитора vegf-r2 для лечения офтальмологического сосудистого заболевания
Reid et al. Erythropoietin in diabetic retinopathy
JP5791064B2 (ja) 医薬用組成物
CN106573012A (zh) 平均分子量低于10000Da的硫酸葡聚糖用于诱导受试者中的血管新生的用途
WO2012105610A1 (ja) 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
US11707445B2 (en) Composition for blocking angiogenesis
US12569498B2 (en) Methods and compositions for the prevention and treatment of ischemia reperfusion injury and infection
CN113456654A (zh) 一种稳定的药物组合物
JP7312340B2 (ja) 水素を含む加齢黄斑変性治療用組成物
CN118766923A (zh) Bmx抑制剂在制备治疗眼底新生血管疾病的药物中的应用
WO2007094193A1 (ja) 血管新生阻害剤及び血管新生を伴う疾病に対する予防又は治療剤並びに食品
KR20250005055A (ko) 아스피린 및 기타 nsaid의 고 침투성 전구약물을 이용한 심혈관 질환의 예방 또는 치료
JP6153838B2 (ja) 血管透過性抑制剤
AU2022271834A1 (en) Use of pelabresib for treating anemias
MX2013010237A (es) Uso de compuestos de vanadio para mantener normaglucemia en un mamifero.
CN116966322A (zh) 一种装载格列本脲及超氧化物歧化酶的纳米材料及其应用
CA3018375C (en) Negative allosteric modulators of mglur5 for use in the treatment of mature brain damages
KR20240102577A (ko) 당뇨망막병증의 예방 및 치료를 위한 다파글리플로진을 함유하는 약제학적 조성물
RU2381028C2 (ru) Способ лечения ожогов конъюнктивы

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130409

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140627

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150324

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150707

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150729

R150 Certificate of patent or registration of utility model

Ref document number: 5791064

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees